Inhibition of Prolactin (PRL)-Induced Proliferative Signals in Breast Cancer Cells by a Molecular Mimic of Phosphorylated PRL, S179D-PRL

Endocrinology

Volumn 144, Issue 12, 2003, Pages 5300-5307

  Schroeder, Matthew D ^a   Brockman, Jennifer L ^a   Walker, Ameae M ^b   Schuler, Linda A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROLACTIN; PROLACTIN RECEPTOR; SERINE; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL COUNT; CELL DIVISION; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CYCLIN D1; DNA-BINDING PROTEINS; HUMANS; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR MIMICRY; PHOSPHORYLATION; PROLACTIN; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0345257112     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0826     Document Type: Article

References (46)

1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA 1998 Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225-268
2. Horseman ND, Zhao WZ, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16:6926-6935
3. Clevenger CV, Furth PA, Hankinson SE, Schuler LA 2003 Role of prolactin in mammary carcinoma. Endocr Rev 24:1-27
4. Vonderhaar BK 2000 Prolactin in human breast cancer development. In: Ethier SP, ed. Endocrine oncology. Totowa, NJ: Humana Press; 101-120
5. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA 1999 Should prolactin be reconsidered as a therapeutic target in human breast cancer. Mol Cell Endocrinol 151:79-87
6. Welsch CW, Nagasawa H 1977 Prolactin and murine mammary tumorigenesis: a review. Cancer Res 37:951-963
7. Boot LM, Muhlbock O, Ropcke G 1962 Prolactin and the induction of mammary tumors in mice. Gen Comp Endocrinol 2:601-603
8. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND 2000 Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19:1077-1084
9. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OGP, Törnell J 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744-2751
10. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA 2003 Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 22:4664-4674
11. Christov K, Swanson SM, Guzman RC, Thordarson G, Jin E, Talamantes F, Nandi S 1993 Kinetics of mammary epithelial cell proliferation in pituitary isografted BALB/c mice. Carcinogenesis 14:2019-2025
12. Hankinson SE, Willett WC, Michaud S, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:629-634
13. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV 1997 Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138:5555-5560
14. Mertani HC, Garcia-Caballero T, Lambert A, Gérard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G 1998 Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 79:202-211
15. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667-674
16. Sinha YN 1995 Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354-369
17. Lorenson MY, Walker AM 2001 Structure-function relationships in prolactin. In: Horseman ND, ed. Prolactin. Boston: Kluwer Academic Press; 189-217
18. Wicks JR, Brooks CL 1995 Biological activity of phosphorylated and dephosphorylated bovine prolactin. Mol Cell Endocrinol 112:223-229
19. Ho TWC, Leong FS, Olaso CH, Walker AM 1993 Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle. Neuroendocrinology 58:160-165
20. 2 cell proliferation. Endocrinology 133:2156-2160
21. Wang YF, Liu JW, Mamidi M, Walker AM 1996 Identification of the major site of rat prolactin phosphorylation as serine 177. J Biol Chem 271:2462-2469
22. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM 1998 Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139:609-616
23. Coss D, Kuo CB, Yang L, Ingleton P, Luben R, Walker AM 1999 Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology 140:5087-5094
24. Bernichtein S, Kinet S, Jeay S, Llovera M, Madern D, Martial JA, Kelly PA, Goffin V 2001 S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist. Endocrinology 142:3950-3963
25. Kuo CB, Wu W, Xu X, Yang L, Chen C, Coss D, Birdsall B, Nasseri D, Walker AM 2002 Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes β-casein gene expression in the rat mammary gland. Cell Tissue Res 309:429-437
26. Naylor MJ, Ginsburg E, Ho TWC, Lismaa TP, Vonderhaar BK, Walker AM, Synick D, Ormandy CJ, Galanin regulation of mammary lobuloalveolar development. Proceedings of the Department of Defense Breast Cancer Research Program, Orlando, FL, 2002 (Abstract P2-20)
27. Wu W, Xu X, Walker AM, Differential modulation of the expression of the long and short form of the PRL receptor and β-casein by unmodified PRL and a molecular mimic of phosphorylated PRL suggests that the short form of the receptor does not act as a dominant negative for signalling resulting in β-casein expression. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2002, p 340 (Abstract)
28. Wu W, Coss D, Sorenson, MY, Kuo B, Xu X, Walker AM 2003 Different biological effects of unmodified PRL and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 42:7561-7570
29. Schroeder MD, Symowicz J, Schuler LA 2002 Prolactin modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16:45-57
30. Brockman JL, Schroeder MD, Schuler LA 2002 Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 16:774-784
31. Schroeder MD, Rose-Hellekant T, Sandgren EP, Schuler LA 2001 Dysregulation of signal transducers and activators of transcription 1, 3, and 5 and prolactin receptors by overexpression of mammary TGFα. Mol Cell Endocrinol 175:173-183
32. Kline JB, Roehrs H, Clevenger CV 1999 Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 274:35461-35468
33. MacGregor GR, Caskey CT 1989 Construction of plasmids that express E. coli β-galactosidase in mammalian cells. Nucleic Acids Res 17:2365
34. Shaw-Bruha CM, Pirrucello SJ, Shull JD 1997 Expression of the prolactin gene in normal and neoplastic human breast tissues and human breast cell lines: promoter usage and alternative mRNA splicing. Br Can Res Treat 44:243-253
35. Fuh G, Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 270:13133-13137
36. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L 2001 Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155:531-542
37. Ormandy CJ, Sutherland RL 1993 Mechanisms of prolactin receptor regulation in mammary gland. Mol Cell Endocrinol 91:C1-C6
38. Hu ZZ, Zhuang L, Dufau ML 1998 Prolactin receptor gene diversity: Structure and regulation. Trends Endocrinol Metab 9:94-102
39. Kelly PA, Djiane J, Postel-Vinay M-C, Edery M 1991 The prolactin/ growth hormone receptor family. Endocr Rev 12:235-251
40. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669
41. Lobenhofer E, Huper G, Iglehart JD, Marks JR 2000 Inhibition of mitogen-actived protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 11:99-110
42. Neve RM, Holbro T, Hynes NE 2002 Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells Oncogene 21:4567-4576
43. Roovers K, Assoian RK 2000 Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22:818-826
44. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 271:16573-16579
45. Kline JB, Rycyzyn MA, Clevenger CV 2002 Characterization of a novel and functional human prolactin receptor isoform (δS1PRLr) containing only one extracellular fibronectin-like domain. Mol Endocrinol 16:2310-2322
46. Hu Z-Z, Meng J, Dufau ML 2001 Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J Biol Chem 276:41086-41094